Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Hancock Jaffe Laboratories stock | $11.54

Own Hancock Jaffe Laboratories stock in just a few minutes.

Fact checked

Hancock Jaffe Laboratories, Inc is a medical devices business based in the US. Hancock Jaffe Laboratories shares (HJLI) are listed on the NASDAQ and all prices are listed in US Dollars. Hancock Jaffe Laboratories employs 12 staff and has a market cap (total outstanding shares value) of USD$17.7 million.

How to buy shares in Hancock Jaffe Laboratories

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Hancock Jaffe Laboratories. Find the stock by name or ticker symbol: HJLI. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Hancock Jaffe Laboratories reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$11.54, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Hancock Jaffe Laboratories, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Hancock Jaffe Laboratories. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Hancock Jaffe Laboratories share price

Use our graph to track the performance of HJLI stocks over time.

Hancock Jaffe Laboratories shares at a glance

Information last updated 2020-12-27.
Latest market closeUSD$11.54
52-week rangeUSD$5.2775 - USD$19.5
50-day moving average USD$8.6044
200-day moving average USD$9.4873
Wall St. target priceUSD$26.25
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.535

Buy Hancock Jaffe Laboratories shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Hancock Jaffe Laboratories stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Hancock Jaffe Laboratories price performance over time

Historical closes compared with the close of $11.54 from 2020-12-11

1 week (2021-01-11) 24.62%
1 month (2020-12-18) 30.84%
3 months (2020-10-16) 2,891.19%
6 months (2020-07-17) 2,792.23%
1 year (2020-01-17) 1,829.77%
2 years (2019-01-18) 630.38%
3 years (2018-01-15) N/A
5 years (2016-01-15) N/A

Hancock Jaffe Laboratories financials

Gross profit TTM USD$-2,174,877
Return on assets TTM -65.33%
Return on equity TTM -179.01%
Profit margin 0%
Book value $2.979
Market capitalisation USD$17.7 million

TTM: trailing 12 months

Shorting Hancock Jaffe Laboratories shares

There are currently 134,621 Hancock Jaffe Laboratories shares held short by investors – that's known as Hancock Jaffe Laboratories's "short interest". This figure is 166.3% up from 50,547 last month.

There are a few different ways that this level of interest in shorting Hancock Jaffe Laboratories shares can be evaluated.

Hancock Jaffe Laboratories's "short interest ratio" (SIR)

Hancock Jaffe Laboratories's "short interest ratio" (SIR) is the quantity of Hancock Jaffe Laboratories shares currently shorted divided by the average quantity of Hancock Jaffe Laboratories shares traded daily (recently around 708531.57894737). Hancock Jaffe Laboratories's SIR currently stands at 0.19. In other words for every 100,000 Hancock Jaffe Laboratories shares traded daily on the market, roughly 190 shares are currently held short.

However Hancock Jaffe Laboratories's short interest can also be evaluated against the total number of Hancock Jaffe Laboratories shares, or, against the total number of tradable Hancock Jaffe Laboratories shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Hancock Jaffe Laboratories's short interest could be expressed as 0.11% of the outstanding shares (for every 100,000 Hancock Jaffe Laboratories shares in existence, roughly 110 shares are currently held short) or 0.1151% of the tradable shares (for every 100,000 tradable Hancock Jaffe Laboratories shares, roughly 115 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Hancock Jaffe Laboratories.

Find out more about how you can short Hancock Jaffe Laboratories stock.

Hancock Jaffe Laboratories share dividends

We're not expecting Hancock Jaffe Laboratories to pay a dividend over the next 12 months.

Have Hancock Jaffe Laboratories's shares ever split?

Hancock Jaffe Laboratories's shares were split on a 1:25 basis on 30 November 2020. So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Hancock Jaffe Laboratories shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for Hancock Jaffe Laboratories shares which in turn could have impacted Hancock Jaffe Laboratories's share price.

Hancock Jaffe Laboratories share price volatility

Over the last 12 months, Hancock Jaffe Laboratories's shares have ranged in value from as little as $5.2775 up to $19.5. A popular way to gauge a stock's volatility is its "beta".

HJLI.US volatility(beta: 1.55)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Hancock Jaffe Laboratories's is 1.5543. This would suggest that Hancock Jaffe Laboratories's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Hancock Jaffe Laboratories overview

Hancock Jaffe Laboratories, Inc., a medical device company, develops and sells tissue based solutions for patients with cardiovascular disease, and peripheral arterial and venous disease in the United States and Europe. It develops and manufactures bioprosthetic implantable devices for cardiovascular diseases, including the VenoValve, a porcine based device to be surgically implanted in the deep venous system of the leg to treat reflux associated with chronic venous insufficiency; and the CoreoGraft, a bovine based off the shelf conduit to be used to revascularize the heart during coronary artery bypass graft surgeries. The company was founded in 1987 and is headquartered in Irvine, California. Hancock Jaffe Laboratories, Inc. operates as a subsidiary of Leman Cardiovascular SA.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site